Sanofi (NASDAQ:SNY) Shares Purchased by Raymond James & Associates

Raymond James & Associates grew its holdings in Sanofi (NASDAQ:SNY - Free Report) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,819,348 shares of the company's stock after buying an additional 129,472 shares during the quarter. Raymond James & Associates owned about 0.11% of Sanofi worth $162,479,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. POM Investment Strategies LLC acquired a new position in Sanofi during the second quarter worth about $25,000. Larson Financial Group LLC grew its holdings in shares of Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company's stock worth $29,000 after acquiring an additional 500 shares during the period. Register Financial Advisors LLC purchased a new position in Sanofi in the 1st quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new position in Sanofi during the first quarter worth $31,000. Finally, Arrow Financial Corp purchased a new stake in Sanofi during the second quarter worth $35,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY traded up $0.07 during trading hours on Friday, reaching $54.93. 1,196,674 shares of the company traded hands, compared to its average volume of 2,019,651. The stock has a market capitalization of $139.12 billion, a PE ratio of 27.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The stock has a fifty day simple moving average of $56.11 and a 200 day simple moving average of $51.58. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $0.95 EPS. As a group, research analysts predict that Sanofi will post 4.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SNY. Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi has an average rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.